Kare is developing a portfolio of non-psychoactive, receptor-targeted therapeutic candidates addressing major global health challenges. Our pipeline is built on our proprietary catalytic platform, enabling scalable production of high-purity ligands for clinical development.
Indication: Moderate to chronic pain
Stage: Preclinical
Mechanism: Selective modulation with fewer CNS side effects
Chronic pain affects over one billion people worldwide and continues to rely heavily on opioid-based treatments. Kare is developing receptor-targeted ligands designed to deliver effective pain relief without the limitations of traditional opioids.
Our approach aims to:
Provide analgesic benefit
Avoid psychoactive effects
Reduce addictive risk
Offer a scalable alternative to opioid-based therapies
By optimizing receptor binding selectivity and limiting central nervous system activation, we are developing a safer, more targeted approach to pain management, with ongoing work in receptor binding assays, selectivity profiling, and preclinical pharmacology evaluation.
Indication: Diet-induced obesity & Type 2 diabetes
Stage: Preclinical
Global obesity rates continue to accelerate, driving demand for safer metabolic therapies.
Kare’s strategy involves peripheral receptor modulation aimed at:
Unlike GLP-1s and other injectable weight-loss therapies, our ligand approach offers potential for differentiated mechanism and improved tolerability.
Focus Areas:
Kare’s catalytic platform enables structural refinement of receptor ligands to tune central versus peripheral activity.
Exploratory studies include:
Our clinical development pathway follows a disciplined pharmaceutical progression, with our long-term objective is to advance select assets through early clinical phases before pursuing strategic partnerships or out-licensing.
Catalytic generation of structurally optimized candidates
High-throughput confirmation of target engagement
Assessment of pharmacology and psychoactivity risk
